Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma

Naoka Murakami; Thiago J. Borges; Michifumi Yamashita; Leonardo V. Riella

doi:10.1093/ckj/sfw024

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma

Naoka Murakami
, Thiago J. Borges
, Michifumi Yamashita
, Leonardo V. Riella

Research output: Contribution to journal › Article › peer-review

100 Scopus citations

Abstract

Immune-checkpoint inhibitors are emerging as revolutionary drugs for certainmalignancies. However, blocking the co-inhibitory signals may lead to immune-related adverse events, mainly in the spectrum of autoimmune diseases including colitis, endocrinopathies and nephritis. Here,we report a case of a 75-year-oldmanwithmetastaticmalignantmelanoma treated with a combination of nivolumab (anti-PD1-antibody) and ipilimumab (anti-CTLA-4 antibody) who developed systemic rash along with severe acute tubulointerstitial nephritis after two doses of combination therapy. Kidney biopsy and peripheral blood immune profile revealed highly proliferative and cytotoxic T cell features. Herein, we discuss the pathophysiology and management of immune checkpoint blockade-related adverse events.

Original language	English
Pages (from-to)	411-417
Number of pages	7
Journal	Clinical Kidney Journal
Volume	9
Issue number	3
DOIs	https://doi.org/10.1093/ckj/sfw024
State	Published - Jun 2016

Keywords

Acute kidney injury
Immune-checkpoint blockade
Interstitial nephritis

Access to Document

10.1093/ckj/sfw024

Cite this

@article{96fc9ed49bd24fb4848d42de42d49133,

title = "Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma",

abstract = "Immune-checkpoint inhibitors are emerging as revolutionary drugs for certainmalignancies. However, blocking the co-inhibitory signals may lead to immune-related adverse events, mainly in the spectrum of autoimmune diseases including colitis, endocrinopathies and nephritis. Here,we report a case of a 75-year-oldmanwithmetastaticmalignantmelanoma treated with a combination of nivolumab (anti-PD1-antibody) and ipilimumab (anti-CTLA-4 antibody) who developed systemic rash along with severe acute tubulointerstitial nephritis after two doses of combination therapy. Kidney biopsy and peripheral blood immune profile revealed highly proliferative and cytotoxic T cell features. Herein, we discuss the pathophysiology and management of immune checkpoint blockade-related adverse events.",

keywords = "Acute kidney injury, Immune-checkpoint blockade, Interstitial nephritis",

author = "Naoka Murakami and Borges, \{Thiago J.\} and Michifumi Yamashita and Riella, \{Leonardo V.\}",

note = "Publisher Copyright: {\textcopyright} The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA.",

year = "2016",

month = jun,

doi = "10.1093/ckj/sfw024",

language = "English",

volume = "9",

pages = "411--417",

journal = "Clinical Kidney Journal",

issn = "2048-8505",

number = "3",

}

TY - JOUR

T1 - Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma

AU - Murakami, Naoka

AU - Borges, Thiago J.

AU - Yamashita, Michifumi

AU - Riella, Leonardo V.

N1 - Publisher Copyright: © The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA.

PY - 2016/6

Y1 - 2016/6

N2 - Immune-checkpoint inhibitors are emerging as revolutionary drugs for certainmalignancies. However, blocking the co-inhibitory signals may lead to immune-related adverse events, mainly in the spectrum of autoimmune diseases including colitis, endocrinopathies and nephritis. Here,we report a case of a 75-year-oldmanwithmetastaticmalignantmelanoma treated with a combination of nivolumab (anti-PD1-antibody) and ipilimumab (anti-CTLA-4 antibody) who developed systemic rash along with severe acute tubulointerstitial nephritis after two doses of combination therapy. Kidney biopsy and peripheral blood immune profile revealed highly proliferative and cytotoxic T cell features. Herein, we discuss the pathophysiology and management of immune checkpoint blockade-related adverse events.

AB - Immune-checkpoint inhibitors are emerging as revolutionary drugs for certainmalignancies. However, blocking the co-inhibitory signals may lead to immune-related adverse events, mainly in the spectrum of autoimmune diseases including colitis, endocrinopathies and nephritis. Here,we report a case of a 75-year-oldmanwithmetastaticmalignantmelanoma treated with a combination of nivolumab (anti-PD1-antibody) and ipilimumab (anti-CTLA-4 antibody) who developed systemic rash along with severe acute tubulointerstitial nephritis after two doses of combination therapy. Kidney biopsy and peripheral blood immune profile revealed highly proliferative and cytotoxic T cell features. Herein, we discuss the pathophysiology and management of immune checkpoint blockade-related adverse events.

KW - Acute kidney injury

KW - Immune-checkpoint blockade

KW - Interstitial nephritis

UR - https://www.scopus.com/pages/publications/84978986900

U2 - 10.1093/ckj/sfw024

DO - 10.1093/ckj/sfw024

M3 - Article

AN - SCOPUS:84978986900

SN - 2048-8505

VL - 9

SP - 411

EP - 417

JO - Clinical Kidney Journal

JF - Clinical Kidney Journal

IS - 3

ER -

Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this